Skip to main content

This is an Educational Presentation On The Role Of Antipsychotic TDM In Clinical Decision Making Presented At The 2022 National College Of Psychiatric And Neurologic Pharmacists.*


For medications such as clozapine, patients and healthcare providers have many situations where TDM is highly relevant in making day-to- day clinical decisions, including differentiating poor adherence with ultrarapid metabolism, and optimizing levels in inadequate responders.

During this session, the faculty will discuss the unique place of clozapine for treatment resistant schizophrenia, and the role of TDM in clozapine dosing during titration, and for monitoring ongoing adherence



Jonathan Meyer, MD
Clinical Professor of Psychiatry University of California, San Diego.
Psychopharmacology Consultant California Department of State Hospitals.

Rob Cotes, MD
Director, Clinical and Research Program for Psychosis Grady Health System.
Associate Professor Emory University School of Medicine Department of Psychiatry and Behavioral Sciences.
Physician Expert, SMI Adviser.

Deanna Kelly, PharmD, BCPP
MPower Professor of Psychiatry, University of Maryland Strategic Partnership: MPowering the State.
Acting Director and Chief, Treatment Research Program (TRP)Maryland.
Psychiatric Research Center (MPRC) University of Maryland School of Medicine.

Megan Ehret, PharmD, MS, BCPP
Professor Department of Pharmacy Practice and Science University of Maryland School of Pharmacy.
SMI Adviser, Pharmacist Consultant.


*The information presented in this seminar was prepared by the faculty and represents their views. Saladax makes no claims other then the intended use for the FDA cleared MyCare Clozapine Assay.

Contact us for more information

region: “na1”,
portalId: “5568226”,
formId: “f86f1ab0-3c0c-4d2d-a2dc-6999395dec43”